Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in theme_biblio_custom() (line 367 of /home/ajphs/public_html/sites/all/modules/biblio/includes/biblio_theme.inc).

Preclinical Pharmacokinetic Evaluation of Pioglitazone Floating Tablets Formulated Employing Olibanum Gum

Asian Journal of Pharmaceutical and Health Sciences,2012,2,2,300-302.
Published:May 2012
Type:Case Report
Authors:
Author(s) affiliations:

Chinna Devi G1*, Bhaskara Rao R2, Lakshmi Narasu M3 

1Department of Pharmacy, Palamuru University, Bandameedipally, Mahabubnagar-509001, Andhra Pradesh, India.

2JNTUH Research Supervisor and Executive, R&D, NATCO Pharma Ltd, Kothur, Mahabubnagar -509001, Andhra Pradesh, India.

3Department of Biotechnology, JNTUH, Hyderabad-500085, Andhra Pradesh, India

Abstract:

The objective of the study is to make a pharmacokinetic evaluation of pioglitazone floating tablets formulated employing olibanum gum in comparison to pioglitazone pure drug in rabbits. The two products were tested in a crossover RBD in healthy rabbits of either sex (n = 6). The plasma concentrations of pioglitazone were determined by a validated HPLC method. From the time versus plasma concentration data various pharmacokinetic parameters (Cmax, Tmax, t1/2, AUC, Ka, and MRT) were calculated. Pioglitazone from the floating tablets formulated was absorbed slowly over longer periods of time in vivo resulting in the maintenance of plasma concentrations within a narrow range over a longer period of time. The absorption rate constant (Ka) was decreased from 1.462 h-1 for pioglitazone pure drug to 0.133 h-1 with the floating tablets. MRT was increased from 9.82 h for pioglitazone pure drug to 13.65 h with the floating tablets. There was no increase in the bioavailability of pioglitazone from the floating tablets developed.

Plasma concentration of Pioglitazone following the oral administration of Pioglitazone